International Application No
PCT/US2004/025592

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/138 A61K31/5375 A61K31/4468 A61K31/538 A61K31/5415
A61K31/40 A61K31/4025 A61K31/445 A61K31/439 A61P25/00
A61P25/28
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BIOSIS, EMBASE, SCISEARCH, WPI Data, PAJ

Category *	NTS CONSIDERED TO BE RELEVANT Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to claim No.
Χ .	STAHL STEPHEN M: "Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition." THE JOURNAL OF CLINICAL PSYCHIATRY. FEB 2003, vol. 64, no. 2, February 2003 (2003-02), pages 110-111, XP008038406 ISSN: 0160-6689 the whole document	1-6
X	WO 02/078629 A (DAVIS MICHAEL; LU KWOK-TUNG (US); RESSLER KERRY J (US); UNIV EMORY (U) 10 October 2002 (2002-10-10) abstract page 3, line 15 - line 21 page 6, line 25 - line 30; claims 1,4-6	1-6

X Further documents are listed in the continuation of box C.	X Patent family members are listed in annex.		
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search	Date of mailing of the international search report		
12 November 2004	- 7. O4. 200 5		
Name and mailing address of the ISA	Authorized officer		
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Hoff, P		

International Application No	
PCT/US2004/025592	2

	ntion) DOCUMENTS CONSIDERED TO BE RELEVANT	
	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Category °	<u> </u>	
Х	WO 03/049724 A (YANG CHARLES RENKIN; LILLY CO ELI (US); BYMASTER FRANKLIN PORTER (US)) 19 June 2003 (2003-06-19) the whole document	1-6
Х	WO 02/053140 A (PHARMACIA AB; SVENSSON TORGNY (SE); WONG ERIK HO FONG (US); UPJOHN CO) 11 July 2002 (2002-07-11) abstract page 2, line 25 - line 31	1-6
	page 8, line 22 - line 31 page 14, line 30 - page 15, line 10	
A	EP 0 721 777 A (LILLY CO ELI) 17 July 1996 (1996-07-17) the whole document	1-6
A	DE 102 44 537 A (GERLOFF CHRISTIAN; PLEWNIA CHRISTIAN (DE)) 10 April 2003 (2003-04-10) the whole document	1-6
A	WO 02/053104 A (EPSTEIN MEL H; SENTION INC (US); WIIG KJESTEN A (US)) 11 July 2002 (2002-07-11) abstract; claims; examples	1-6
ı		

Information on patent family members

International Application No
PCT/US2004/025592

Patent document ordative Patent family member(s) Publication date						
WU 02078029	Patent document cited in search report					
NO 03049724	WO 02078629	A	10-10-2002	EP JP WO	1383465 A2 2004530666 T 02078629 A2	28-01-2004 07-10-2004 10-10-2002
FP 1353675 A2 22-10-2003 JP 2004517112 T 10-06-2004 W0 02053144 A2 11-07-2002 US 2002156067 A1 24-10-2002 US 2002156067 A1 24-10-2002 24-10-2002 24-10-2002 24-10-2002 24-10-2002 24-10-2002 24-10-2002 24-10-2002 24-10-2002 24-10-2002 24-10-2002 24-10-2002 24-10-2002 24-10-2002 24-10-2002 24-10-2002 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-2003 24-10-20	WO 03049724	A	19-06-2003	BR CZ EP HR SK WO	0213581 A 2467802 A1 20040709 A3 1458368 A1 20040528 A2 2442004 A3 03049724 A1	24-08-2004 19-06-2003 13-10-2004 22-09-2004 31-10-2004 01-12-2004 19-06-2003
AT 222757 T 15-09-2002 AU 688665 B2 12-03-1998 AU 4693896 A 31-07-1996 BR 9606903 A 21-10-1997 CA 2209735 A1 18-07-1996 CN 1168095 A 17-12-1997 CZ 9702145 A3 14-01-1998 DE 69623141 D1 02-10-2002 DE 69623141 D1 02-10-2002 DE 69623141 T2 24-04-2003 DK 721777 T3 07-10-2002 EP 0721777 A2 17-07-1996 ES 2181845 T3 01-03-2003 FI 972922 A 09-07-1997 HU 9801283 A2 28-06-1999 JP 10512262 T 24-11-1998 NO 973170 A 02-09-1997 NZ 301500 A 28-07-2000 PL 321273 A1 24-11-1997 PT 721777 T 29-11-2002 RO 118374 B1 30-05-2003 RU 2163802 C2 10-03-2001 SI 721777 T1 28-02-2003 TR 9700627 T1 21-01-1998 WO 9621430 A1 18-07-1996	WO 02053140	Α	11-07-2002	EP JP WO	1353675 A2 2004517112 T 02053140 A2	22-10-2003 10-06-2004 11-07-2002
WO 02053104 A 11-07-2002 WO 02053104 A2 11-07-2002	EP 0721777	A	17-07-1996	ATUURA CCCDE BE FIUPOZLTORUIR	222757 T 688665 B2 4693896 A 9606903 A 2209735 A1 1168095 A 9702145 A3 69623141 D1 69623141 T2 721777 T3 0721777 A2 2181845 T3 972922 A 9801283 A2 10512262 T 973170 A 301500 A 321273 A1 721777 T 118374 B1 2163802 C2 721777 T1 9700627 T1	15-09-2002 12-03-1998 31-07-1996 21-10-1997 18-07-1996 17-12-1997 14-01-1998 02-10-2002 24-04-2003 07-10-2002 17-07-1996 01-03-2003 09-07-1997 28-06-1999 24-11-1998 02-09-1997 28-07-2000 24-11-1997 29-11-2002 30-05-2003 10-03-2001 28-02-2003 21-01-1998 18-07-1996
MIT 6/622104 D 22 0/ 2002 H	DE 10244537					
	WO 02053104		A 11-07-200			

International application No. PCT/US2004/025592

Box II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)					
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:					
1. 🗶	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Although claims 1,3-6 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.					
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such because they relate to parts of the International Search can be carried out, specifically: an extent that no meaningful International Search can be carried out, specifically:					
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).					
Box II	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)					
This In	ternational Searching Authority found multiple inventions in this international application, as follows:					
	see additional sheet					
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.					
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.	İ				
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:	i i				
4. [,	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-6 (all partially)	Section 1.				
Rem	ark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.					

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-6 (all partially)

Use of atomoxetine or a compound of formula (I) for treating a learning disability

2. claims: 1-5 (all partially)

Use of racemic reboxetine or (S,S) reboxetine for treating a learning disability ${\sf S}$

3. claims: 1-5 (all partially)

Use of a compound of formula (IA) for treating a learning disability

4. claims: 1-5 (all partially)

Use of a compound of formula (IB),(IC) or (IG) for treating a learning disability ${\bf r}$

5. claims: 1-5 (all partially)

Use of a compound of formula (ID) for treating a learning disability ${\bf r}$

6. claims: 1-5 (all partially)

Use of a compound of formula (IE) for treating a learning disability

7. claims: 1-5 (all partially)

Use of a compound of formula (IF) for treating a learning disability

8. claims: 1,2,6 (all partially)

Use of atomoxetine or a compound of formula (I) for treating a Motor Skills Disorder

9. claims: 1,2 (all partially)

Use of racemic reboxetine or (S,S) reboxetine for treating a Motor Skills Disorder

10. claims: 1,2 (all partially)

Use of a compound of formula (IA) for treating a Motor Skills Disorder

11. claims: 1,2 (all partially)

Use of a compound of formula (IB),(IC),(IG) for treating a Motor Skills Disorder ${\bf R}$

12. claims: 1,2 (all partially)

Use of a compound of formula (ID) for treating a Motor Skills Disorder

13. claims: 1,2 (all partially)

Use of a compound of formula (IE) for treating a Motor Skills Disorder

14. claims: 1,2 (all partially)

Use of a compound of formula (IF) for treating a Motor Skills Disorder